Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Health and Human Services (HHS), specifically the National Cancer Institute (NCI) and Center for Cancer Research, has issued a Notice of Intent to award a sole-source contract for Nucleic acid–based reagents for in vivo transient protein expression. The intended awardee is the Trustees of The University of Pennsylvania - Penn Medicine.
Scope of Work
The requirement is for nucleic acid-based reagents to investigate preventive strategies against viral infections, including HIV/Simian Immunodeficiency virus (SIV) and HTLV, in preclinical models. These reagents will express viral antigens for preventive treatment. The use of these specific reagents is critical for consistency with prior preclinical studies conducted by the AMRVS, ensuring reproducibility and continuity in experimental design and data analysis, as variations in formulation, synthesis, and purity from different suppliers could complicate results.
Contract & Timeline
- Type: Notice of Intent (Presolicitation) for a Sole-Source Award
- Intended Awardee: Trustees of The University of Pennsylvania - Penn Medicine
- Product Service Code: 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits And Sets)
- Published Date: January 30, 2026
- Response Date (for objections): February 14, 2026, 6:00 PM EST
Additional Notes
This notice is for informational purposes only and is not a request for competitive quotations or capability statements. Interested parties are explicitly instructed not to call or submit questions/inquiries via email concerning this presolicitation notice update. Any objections to this sole-source intent must be submitted by the response date.